Sand Grove Capital Management has increased its holding in the pharmaceutical company Egetis Therapeutics to approximately 16.4 million shares, from 14.7 million shares previously. The holding consequently amounts to 3.525 percent of the shares and votes.
In addition, Sand Grove holds financial instruments corresponding to 1.502 percent of the votes. The total holding therefore amounts to 5.027 percent of the votes.
This is disclosed in a flagging notification.
